Does Rallies show Form 4 insider transactions for ATOS?

Yes. Rallies tracks ATOS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is ATOS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ATOS. It does not provide personalized investment advice.

ATOS (Atossa Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Atossa Therapeutics, Inc. Common Stock (ATOS) is a publicly traded Healthcare sector company. As of May 20, 2026, ATOS trades at $5.00 with a market cap of $41.16M and a P/E ratio of -1.20. ATOS moved +2.00% today. Year to date, ATOS is -47.72%; over the trailing twelve months it is -65.75%. Its 52-week range spans $3.76 to $24.90. Analyst consensus is strong buy with an average price target of $23.00. Rallies surfaces ATOS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading ATOS stock inside the company?

Recent ATOS insider activity includes QUAY STEVEN C bought 11.24K, Remmel H. Lawrence bought 10.00K, Finn Jonathan bought 25.00K, WEAVER GREGORY L sold 50.00K, and WEAVER GREGORY L bought 50.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

ATOS Key Metrics

Key financial metrics for ATOS
Metric	Value
Price	$5.00
Market Cap	$41.16M
P/E Ratio	-1.20
EPS	$-4.04
Dividend Yield	0.00%
52-Week High	$24.90
52-Week Low	$3.76
Volume	36.52K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-34.77M
Gross Margin	0.00%

Recent ATOS Insider Trades

QUAY STEVEN C bought 11.24K (~$9.89K) on May 21, 2025.
Remmel H. Lawrence bought 10.00K (~$7.00K) on Mar 26, 2025.
Finn Jonathan bought 25.00K (~$44.25K) on Apr 10, 2024.
WEAVER GREGORY L sold 50.00K (~$32.50K) on Nov 15, 2023.
WEAVER GREGORY L bought 50.00K (~$48.50K) on Jun 20, 2023.

Latest ATOS News

Atossa’s Manuscript on (Z)-Endoxifen Utrophin Modulation Accepted for Publication — May 20, 2026
Atossa Sees Q1 Operating Costs Climb 35% to $9.9M as FDA Awards Orphan, RPD Status for (Z)-Endoxifen — May 8, 2026
Atossa Wins FDA Rare Pediatric Designation, PRV Worth $100–$205M — May 4, 2026
Atossa Therapeutics’ Expenses Jump 35% to $37.1M, Gains FDA Rare Disease Designations — Mar 25, 2026
Atossa Hires Two Clinical Directors for Breast Cancer and Rare Disease Programs — Mar 19, 2026

ATOS Analyst Consensus

3 analysts cover ATOS: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $23.00.

Common questions about ATOS

Who is trading ATOS stock inside the company?: Recent ATOS insider activity includes QUAY STEVEN C bought 11.24K, Remmel H. Lawrence bought 10.00K, Finn Jonathan bought 25.00K, WEAVER GREGORY L sold 50.00K, and WEAVER GREGORY L bought 50.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for ATOS?: Yes. Rallies tracks ATOS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is ATOS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ATOS. It does not provide personalized investment advice.